Menu
Recruiting NCT06911099

Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation (ATRIAL-MR)

Observational Atrial Functional Mitral Regurgitation Mitral Insufficiency

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Atrial Functional Mitral Regurgitation, Mitral Insufficiency. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Canada, France, Germany, Italy +1
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation

Overview

This investigator-initiated, multicenter, international, retrospective registry aims to investigate outcomes of patients with atrial functional mitral regurgitation, as treated in clinical routine.

Primary outcome measures

  • Composite of all-cause mortality and heart-failure related rehospitalitzation [Time frame: 12 months]
Secondary outcome measures (7)
  • Residual Mitral Regurgitation ≤1+ [Time frame: 12 months]
  • All-cause mortality [Time frame: 12 months]
  • Cardiovascular mortality [Time frame: 12 months]
  • Heart failure related rehospitalization [Time frame: 12 months]
  • Unplanned mitral valve intervention [Time frame: 12 months]
  • New York Heart Association (NYHA) class III or IV [Time frame: 12 months]
  • 6 Minute Walking Distance [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • functional mitral regurgitation
  • left ventricular ejection fraction ≥50%

Exclusion criteria

  • age under 18 years
  • known regional wall movement disorders

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Germany · 10 centers
  • LMU Klinikum — Munich
  • University Hospital Cologne — Cologne
  • HDZ Bad Oeynhausen — Bad Oeynhausen
  • Heart Center Bonn — Bonn
  • University Hospital of Düsseldorf — Düsseldorf
  • University Heart and Vascular Center Hamburg — Hamburg
  • University Hospital Schleswig-Holstein — Kiel
  • Heart Center Leipzig at University of Leipzig — Leipzig
  • … and 2 more centers
Spain · 5 centers
  • Hospital Clinic of Barcelona — Barcelona
  • Reina Sofia University Hospital — Córdoba
  • University Hospital of León — León
  • Asturias Central University Hospital — Oviedo
  • University Hospital Alvaro Cunqueiro — Vigo
Italy · 3 centers
  • University of Brescia — Brescia
  • San Raffaele University Hospital — Milan
  • University of Pisa — Pisa
France · 2 centers
  • Bordeaux University Hospital — Bordeaux
  • University Hospital Center of Nantes — Nantes
United States · 1 center
  • Montefiore Medical Center — The Bronx
Canada · 1 center
  • St. Michael's Hospital — Toronto

Identifiers

NCT: NCT06911099 · 24-1121

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗